Team approach aims to boost cancer pill adherence and safety

NCT ID NCT01370980

Completed Disease control Sponsor: Center for Primary Care and Public Health (Unisante), University of Lausanne, Switzerland Source: ClinicalTrials.gov ↗

First seen Jul 17, 2026 · Last updated Jul 17, 2026

Summary

This study tests a support program that brings together oncologists, pharmacists, doctors, and nurses to help cancer patients take their oral medications as prescribed. The goal is to improve treatment effectiveness and patient safety by ensuring better communication and follow-up. Adults 18 and older being treated for cancer with specific oral drugs can take part.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: a support program involving oncologists, pharmacists, physicians, and nurses to improve medication adherence
What this could lead to: If successful, this approach could improve how well cancer patients follow their oral treatment plans and reduce complications.
What could go wrong: This is a small, early-stage study with only 43 participants, so results may not apply broadly. The program's success depends on many factors, including patient motivation.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cancer Medication Adherence neoplasm Patient Acceptance of Health Care Patient Compliance

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CANCER

Contacts and locations

Show contact details

Locations

Policlinique Médicale Universitaire and Centre pluridisciplinaire d'oncologie, CHUV

Lausanne, Canton of Vaud, 1010, Switzerland

More trials for these conditions

Other studies related to the condition(s) this trial covers.